Inhibrx Biosciences (INBX) Research & Development (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Research & Development data on file, last reported at $25.3 million in Q4 2025.

• On a quarterly basis, Research & Development fell 24.03% year-over-year to $25.3 million in Q4 2025; TTM through Dec 2025 was $113.0 million, a 44.52% decrease from a year earlier, with the FY2025 full-year figure at $113.0 million, down 44.52% from the prior year.
• Research & Development for Q4 2025 stood at $25.3 million, down from $28.5 million in the prior quarter.
• Over the last five years, Research & Development for INBX reached as high as $82.1 million in Q4 2023 and fell as low as $22.3 million in Q2 2025.
• Historically, Research & Development has averaged $42.8 million across 3 years, with a median of $36.9 million in 2025.
• Across the five-year window, Research & Development soared 98.3% in 2024 and tumbled 67.08% in 2025, its largest moves.
• Year by year, Research & Development stood at $82.1 million in 2023, then tumbled by 59.35% to $33.4 million in 2024, then dropped by 24.03% to $25.3 million in 2025.
• Per Business Quant data, the three most recent Research & Development figures were $25.3 million in Q4 2025, $28.5 million in Q3 2025, and $22.3 million in Q2 2025.